GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...

A renowned name in rare blood disorders research, Prof. Khaled Musallam has become the first Arab to receive the Clinical ...

Congress, held from June 12 to June 15 in Milan, Italy, updated results from the Phase II registrational iMMagine-1 study ...

First clinical data for INCA033989, a novel monoclonal antibody from Incyte (Nasdaq: INCY) targeting CALR-mutant ...